Back to results
US 9,119,815 B2Granted
Combined measles-malaria vaccine
AssigneeCadila Healthcare Limited
InventorsReinhard Glueck, Agata Fazio, Viviana Giannino, Martin A Billeter
Life of this patent
Estimating the term…
Loading patent…
Loading patent…
AssigneeCadila Healthcare Limited
InventorsReinhard Glueck, Agata Fazio, Viviana Giannino, Martin A Billeter
Estimating the term…
A combined measles-malaria vaccine containing different attenuated recombinant measles-malaria vectors comprising a heterologous nucleic acid encoding several Plasmodium falciparum antigens is described. Preferably, it relates to viral vectors that comprise nucleic acids encoding the circumsporozoite (CS) protein of P. falciparum, the merozoite surface protein 1 (MSP-1) of P. falciparum, and its derivatives (p-42; p-83-30-38) in its glycosylated and secreted forms, and apical membrane antigen1 (AMA1) of P. falciparum, in its anchored or secreted form. The viral vector stems from an attenuated measles virus, based on a strain that is used as a vaccine and is efficient in delivering the gene of interest and that binds to and infects the relevant immune cells efficiently.
A combined measles-malaria immunogenic composition comprising a recombinant measles vaccine virus which expresses MSP1 malaria antigens and measles antigens capable of eliciting immune response against measles and malaria wherein the nucleotide sequence of MSP1 malaria antigen is selected from SEQ ID NO:7 and SEQ ID NO:8.
A measles vaccine virus vector comprising the nucleotide sequence of an antigen of malaria wherein the nucleotide sequence is selected from SEQ ID NO:3 to SEQ ID NO:12.
A measles vaccine virus vector comprising the nucleotide sequence of an antigen of malaria, wherein the measles vaccine virus vector further comprises the nucleotide sequence selected from SEQ ID NO:1 and SEQ ID NO:2.
A combined measles-malaria immunogenic composition comprising a recombinant measles vaccine virus which expresses MSP1 malaria antigens and measles antigens capable of eliciting immune response against measles and malaria, wherein recombinant measles vaccine virus comprises the following sequences:
Dependencies are inferred from the claim text.